US: 800.298.5699
Int'l: +1.240.747.3093
 
Matching geography
Reports matching your search in:
 
 
Join Alert Me now!
Receive bi-weekly email alerts on new market research

Sign up today!
 

Ophthalmology: market research reports

A portion of ophthalmology that resists change unlike some other specialties is the consumer reluctance to undertake a procedure that may have side effects associated with vision like refractive laser correction. Any side effects concerning eyes/vision is typically avoided as much as possible especially if there are other options.
Typically if the out-of pocket price for a life-enhancing procedure is within the budget of a consumer, the patient has a strong desire to get the procedure, and other factors are present that allow for it, the procedure is undertaken. In laser correction there has been skepticism which has diminished as more patients undertake the procedure with good results. While new ideas, breakthrough technologies, cost efficiencies, increased productivity,and new markets are the keys to growth and competitiveness, most people [work force; consumers; academics; politicians] are more confident in familiar environments. They will resist change unless their job, livelihood, or lifestyles are threatened.

This phenomenon is partly responsible for the trend toward closing solo and small group practices to join vision care networks. Though this experience exists more in general medical practices and some pecialties, ophthalmologists also face the threat of practitioners [osteopathic physicians, doctors of optometry] replacing eye MDs—an intrusion on their medical training, skills, and specialty. However increasing healthcare costs, and economic changes sometimes force shifts in the typical work pattern of healthcare providers. One example is a change that has happened in states across the U.S. allowing optometrists to diagnose and treat glaucoma.

RSS Feeds

Ophthalmology market research reports and industry analysis

< prev 1    3  4  5  6  7  8  9  10  
Ophthalmics Partnering Terms & Agreements
8/1/2014 | published by: Current Partnering
... or development stage whereby the licensee obtains a right or an option right to license the licensors opthalmics technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. This report ...  |  read more...
USD 1,995
Glaucoma Partnering 2009-2014
8/1/2014 | published by: Current Partnering
... by value •Deals listed by company A-Z, industry sector, stage of development, technology type Glaucoma Partnering 2009-2014 provides understanding and access to the glaucoma partnering deals and agreements entered into by the worlds leading healthcare ...  |  read more...
USD 695
Global Cytomegalovirus Retinitis Market : 2014-2018
8/13/2014 | published by: TechNavio - Infiniti Research Ltd.
... Roche Ltd., Gilead Sciences Inc., Hospira Inc. and Shire plc. Other Prominent Vendors in the market are: Auritec Pharmaceuticals, Chimerix Pharmaceuticals, Isis Pharmaceuticals, pSivida and Sanofi. Commenting on the report, an analyst from TechNavio’s team ...  |  read more...
USD 2,500
Age-related Macular Degeneration Partnering 2009-2014
8/1/2014 | published by: Current Partnering
... age-related macular degeneration partnering deals •Top age-related macular degeneration deals by value •Deals listed by company A-Z, industry sector, stage of development, technology type Age-related Macular Degeneration Partnering 2009-2014 provides understanding and access to the ...  |  read more...
USD 695
Conjunctivitis Partnering 2009-2014
8/1/2014 | published by: Current Partnering
... by value •Deals listed by company A-Z, industry sector, stage of development, technology type Conjunctivitis Partnering 2009-2014 provides understanding and access to the conjunctivitis partnering deals and agreements entered into by the worlds leading healthcare ...  |  read more...
USD 695
Dry Eye Partnering 2009-2014
8/1/2014 | published by: Current Partnering
... deals •Top dry eye deals by value •Deals listed by company A-Z, industry sector, stage of development, technology type Dry Eye Partnering 2009-2014 provides understanding and access to the dry eye partnering deals and agreements ...  |  read more...
USD 695
Ophthalmics Deals and Alliances of 2013
8/1/2014 | published by: Current Partnering
... during 2013. Using these reports, dealmakers will effectively and efficiently gain insight into the partnering activities of the past year. The report series allows you to view all the partnering and alliances deals announced worldwide. ...  |  read more...
USD 1,495
Glaucoma - Pipeline Review, H2 2014
7/31/2014 | published by: Global Markets Direct
... Glaucoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It ...  |  read more...
USD 2,000
Global Retinal Vein Occlusion Market : 2014-2018
7/23/2014 | published by: TechNavio - Infiniti Research Ltd.
... AG, F. Hoffmann-La Roche Ltd., Novartis AG and Regeneron Pharmaceuticals Inc. Other prominent vendors in the market are: Alimera Sciences, Bristol-Myers Squibb, NicOx, Santen Pharmaceutical and Valeant Pharmaceuticals. Commenting on the report, an analyst from ...  |  read more...
USD 2,500
Global Macular Edema Market : 2014-2018
7/7/2014 | published by: TechNavio - Infiniti Research Ltd.
... F. Hoffmann-La Roche Ltd., Novartis AG, Regeneron Pharmaceuticals Inc., Alcon Inc., Alimera Sciences Inc., Allergan Inc., Ampio Pharmaceuticals Inc., iCo Therapeutics Inc.,Pfizer Inc., Santen Pharmaceutical Co. Ltd. Commenting on the report, an analyst from TechNavio’s ...  |  read more...
USD 2,500
Global Ophthalmic Diagnostic Devices Market : 2014-2018
7/14/2014 | published by: TechNavio - Infiniti Research Ltd.
... Commenting on the report, an analyst from TechNavio’s team said: “The minimally invasive procedure, Laser Vision Correction, popularly called LASIK, has become extremely popular in the Healthcare industry. In the US alone, about 19 million ...  |  read more...
USD 2,500
Open-Angle Glaucoma - Pipeline Review, H2 2014
7/15/2014 | published by: Global Markets Direct
... therapeutic development for Open-Angle Glaucoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news ...  |  read more...
USD 2,000
Retinal Degeneration - Pipeline Review, H1 2014
6/30/2014 | published by: Global Markets Direct
... therapeutic development for Retinal Degeneration, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news ...  |  read more...
USD 2,000
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H1 2014
6/30/2014 | published by: Global Markets Direct
... Exudative) Macular Degeneration’s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Wet (Neovascular / Exudative) Macular Degeneration, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of ...  |  read more...
USD 2,000
Ophthalmic Drugs Market Forecast 2014-2024
6/16/2014 | published by: Visiongain
... you potential revenues to 2024, assessing data, trends, opportunities and prospects there. Our 337-page report provides 198 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our ...  |  read more...
USD 2,986
Ophthalmics Partnering Terms & Agreements
7/1/2014 | published by: Current Partnering
... or development stage whereby the licensee obtains a right or an option right to license the licensors opthalmics technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. This report ...  |  read more...
USD 1,995
Optometrists - Industry Market Research Report - in the US
5/30/2014 | published by: IBISWorld
... delayed eye examinations begin to make appointments again. Aging baby boomers and a rise in the number of insured individuals will likely aid business significantly for industry operators, but competition from eye glasses and contact ...  |  read more...
USD 1,020
Global Uveitis Market 2014-2018
5/30/2014 | published by: TechNavio - Infiniti Research Ltd.
... Inc., Bausch & Lomb Inc., Artielle ImmunoTherapeutics Inc., Enzo Biochem Inc., Hanall Pharmaceutical Co. Ltd., Lux Biosciences Inc., OphthaliX Inc., Regeneron Pharmaceuticals Inc., TopiVertLtd., pSivida Corp., XOMA Corp., Santen Pharmaceutical Co. Commenting on the report, ...  |  read more...
USD 2,500
Juvenile Macular Degeneration (Stargardt Disease) - Pipeline Review, H1 2014
5/30/2014 | published by: Global Markets Direct
... therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Juvenile Macular Degeneration (Stargardt Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of ...  |  read more...
USD 2,000
Dry (Atrophic) Macular Degeneration - Pipeline Review, H1 2014
6/25/2014 | published by: Global Markets Direct
... report provides comprehensive information on the therapeutic development for Dry (Atrophic) Macular Degeneration, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule ...  |  read more...
USD 2,000
Global Age-Related Macular Degeneration (AMD) Market 2014-2018
6/6/2014 | published by: TechNavio - Infiniti Research Ltd.
... AG, F. Hoffmann-La Roche Ltd., Novartis AG, Regeneron Pharmaceuticals Inc., Acucela Inc., Advanced Cell Technology Inc., Alexion Pharmaceuticals Inc., Alimera Sciences Inc., Allergen Inc., Allergo Opthalmics LLC, Avalanche Biotechnologies Inc., Gilead Sciences Inc., GlaxoSmithKline plc, ...  |  read more...
USD 2,500
Global Diabetic Retinopathy Market 2014-2018
6/13/2014 | published by: TechNavio - Infiniti Research Ltd.
... Ltd., Novartis AG , Pfizer Inc., Regeneron Pharmaceuticals Inc., Valeant Pharmaceuticals International Inc. , Abbott Laboratories Ltd., Alcon Laboratories Inc., Alimera Sciences Inc., Allergan Inc., Ampio Pharmaceuticals Inc., Antisense Therapeutics Ltd., Bausch & Lomb Inc., ...  |  read more...
USD 2,500
Sustained Release Ocular Drug Delivery Systems Market, 2014-2024
4/8/2014 | published by: Roots Analysis
... Several barriers have to be overcome for successful ocular drug delivery. For example, dilution of a drug by tears, clearance of a drug by the lymphatic system of conjunctiva, drug permeation issues with respect to ...  |  read more...
USD 1,899
Dry Eye Syndrome: Clinical Trial Tracker
4/29/2014 | published by: Roots Analysis
... no cure for dry eye syndrome, but there are treatments to control its symptoms. The prevalence of dry eye syndrome primarily increases with age, and has an estimated incidence of 15% in persons over the ...  |  read more...
USD 799
Dry Eye Partnering 2009-2014
4/1/2014 | published by: Current Partnering
... deals Top dry eye deals by value Deals listed by company A-Z, industry sector, stage of development, technology type Dry Eye Partnering 2009-2014 provides understanding and access to the dry eye partnering deals and agreements ...  |  read more...
USD 695
< prev 1    3  4  5  6  7  8  9  10